Affymax names new president and COO
This article was originally published in Scrip
John Orwin has joined the US biopharmaceutical company Affymax as president and chief operating officer. In the newly created position, he will provide leadership in commercial, manufacturing and medical affairs areas. Mr Orwin was previously senior vice-president of the BioOncology business unit at Genentech, where he was responsible for all marketing, sales, business unit operations and pipeline brand management for the company's oncology portfolio in the US. He has also worked at Alza Pharmaceuticals, Sangstat Medical, Rhone-Poulenc Rorer Pharmaceuticals and Schering-Plough.